Spirea

Spirea is at the forefront of revolutionising cancer and beyond with our cutting-edge ELIVATE linker technology. Our innovative approach significantly expands the payload repertoire for antibody-drug conjugates (ADCs), enabling the next generation of targeted therapies. By leveraging ELIVATE’s multivalent capabilities, we optimise therapeutic outcomes, ensuring precise drug delivery and enhanced pharmacokinetics. Our dedicated team of experts is committed to advancing our proprietary ADC pipeline and forming strategic partnerships to maximise the potential of our technology. Join us on our mission to transform patient care and deliver groundbreaking treatments across a wide range of diseases. Explore how Spirea is unlocking the full potential of ADCs at www.spirea.co.uk